Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients

This study has been completed.
Sponsor:
Information provided by:
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT00187200
First received: September 10, 2005
Last updated: April 6, 2010
Last verified: April 2010

September 10, 2005
April 6, 2010
January 2005
April 2010   (final data collection date for primary outcome measure)
Not Provided
CRT responder rate
Complete list of historical versions of study NCT00187200 on ClinicalTrials.gov Archive Site
  • Quality of life
  • Cardiac reverse remodeling
  • NYHA class progression
  • Left ventricular ejection fraction (LVEF)
  • HF related hospitalizations
  • 6 minute hall walk
  • Quality of life
  • Cardiac reverse remodeling
  • NYHA class progression
  • LVEF
  • HF related hospitalizations
Not Provided
Not Provided
 
Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients
RESPONSE HF - Response of Cardiac Resynchronization Therapy Optimization With V-V Timing in Heart Failure Patients

The purpose of the study is to evaluate the benefit of interventricular (V-V) delay optimization in reducing the non-responder rate in patients with cardiac resynchronization defibrillator (CRT-D) devices. The primary endpoint of this study is CRT responder rate.

For patients enrolled with new CRT-D systems, patients are considered non-responders if BOTH of the following requirements are fulfilled:

  • < 10% improvement in 6-minute hall walk, and
  • no class improvement or worsening in New York Heart Association (NYHA) scale.

For those receiving CRT-D devices as replacements of older CRT-D systems, patients are considered non-responders if BOTH of the following requirements are fulfilled:

  • > 1 heart failure (HF) related hospitalization, and
  • no class improvement or worsening in NYHA scale.

Study Methods

  • This is a prospective, randomized (simultaneous BiV pacing vs. sequential BiV pacing) study.
  • Any patient that receives an FDA approved SJM CRT-D with V-V timing is eligible for enrollment.
  • At 3 months post enrollment (or at implant for CRT-D replacements), patients screened as non-responders are randomized to either simultaneous or sequential BiV pacing. Patients requiring a replacement CRT-D device that are identified as non-responders to CRT are enrolled at the screening/randomization visit.
  • Patients are followed for a period of 6 months post randomization:

    • Enrollment (1 week pre CRT-D implant to < 2 weeks post CRT-D implant)
    • Screening/Randomization Visit (3 months post enrollment)
    • Follow-up Visit (6 months post randomization)
  • Total # of centers - 80 centers
  • Sample size - 800 patients screened for CRT non-responders (200 randomized patients)
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Heart Failure
  • Device: CRT-D system
  • Device: Optimization of interventricular intervals
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has a standard indication for a CRT-D.
  • Patient has the ability to complete a 6-minute hall walk with the only limiting factor to be fatigue or shortness of breath.
  • Patient is geographically stable and willing to comply with the required follow-up schedule.
  • Prior to 1 month of randomization, patient's HF medications are maintained stable and remain stable throughout the study.
  • Patients requiring a CRT-D replacement must comply with BOTH of the following:

    • > 1 HF related hospitalization
    • No class improvement or worsening in NYHA scale

Exclusion Criteria:

  • Patient's life expectancy is less than 12 months.
  • Patient has had cardiac surgery within 6 months of enrollment.
  • Patient has an epicardial ventricular lead system.
  • Patient is less than 18 years old.
  • Patient is pregnant.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00187200
CRD299
Not Provided
Dr. Raul Weiss, Ohio State University
St. Jude Medical
Not Provided
Principal Investigator: Raul Weiss, MD Ohio State University
St. Jude Medical
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP